Phase 1/2a Study of Belantamab Mafodotin in Relapsed or Refractory AL Amyloidosis

Conditions

• AL Amyloidosis
• Amyloidosis

Interventions

• DRUG: Belantamab mafodotin 2.5 mg/kg (8 weeks)
• DRUG: Belantamab mafodotin 1.9 mg/kg (8 weeks)
• DRUG: Belantamab mafodotin 1.4 mg/kg (12 weeks)
• DRUG: Belantamab mafodotin 1.9 mg/kg (12 weeks)
• DRUG: Belantamab mafodotin every 8 weeks or 12 weeks as determined by Part 1 recommended dosages
• DRUG: Belantamab mafodotin 1.0 mg/kg (12 weeks)

Sponsor

University of Texas Southwestern Medical Center

Collaborators

• [object Object]